Form 4: Nurix Therapeutics CLO Sells Shares via 10b5-1 Plan

Nurix Therapeutics Chief Legal Officer Christine Ring sold 5,394 shares of common stock under a pre-arranged trading plan.

Summary

• Christine Ring, Chief Legal Officer of Nurix Therapeutics, Inc. (NRIX), sold 5,394 shares of common stock.
• The transaction occurred on May 1, 2026.
• The shares were sold at a weighted average price of $16.7606 per share.
• The sale was executed pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person.
• Following the transaction, the reporting person retains beneficial ownership of 26,453 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed via a pre-planned 10b5-1 arrangement, which is standard practice for executive financial management.

Positives

• The sale was conducted under a pre-established Rule 10b5-1 trading plan, which is a standard mechanism for executives to sell shares without triggering insider trading concerns.

Negatives

• The transaction represents a reduction in the direct equity stake held by a key member of the executive leadership team.

Risks

• Executive stock sales can sometimes be perceived negatively by the market as a signal of management's view on the company's valuation.

Future Outlook

No forward-looking guidance or operational outlook was provided in this filing.

Management Comments

• The reporting person has committed to providing full information regarding the number of shares sold at each separate price within the range upon request.

Industry Context

StockSavvy.ai notes that routine insider selling under 10b5-1 plans is a common practice in the biotechnology sector, often used for liquidity or tax planning purposes rather than reflecting a change in corporate strategy.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate officers to manage equity holdings while maintaining regulatory compliance.

Stakeholder Impact

• Minimal impact on shareholders as the sale was pre-planned and represents a small portion of the executive's total holdings.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Nurix Therapeutics, NRIX, Insider Trading, Form 4, SEC Filing, Executive Compensation